EANS-Adhoc: SYGNIS Pharma AG
SYGNIS Pharma AG decides on increase in share capital

  ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
  adhoc with the aim of a Europe-wide distribution. The issuer is solely
  responsible for the content of this announcement.

Ad-hoc release

SYGNIS Pharma AG decides on increase in share capital

Heidelberg, 20 July 2011 -  Today the Management Board of  the  Heidelberg-based
SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard), with  the
approval of the Supervisory Board, decided to increase the equity  capital  from
euro 13,752,881 to up to euro 16,988,853, by  issuing  up  to  3,235,972  no-par
value bearer shares from authorised capital. The new shares are  to  be  offered
to the shareholders at a subscription price of euro 2.00 per new share.

The shareholders can subscribe to the new shares with  dividend  rights  from  1
April 2010 in a 17:4 ratio within the subscription period which  lasts  from  26
July until 9  August  2011  (full  days  included).  Moreover,  as  part  of  an
additional purchase existing shareholders have the opportunity to subscribe  for
additional shares which have not been subscribed by other shareholders.

In June 2011 dievini Hopp BioTech holding GmbH & Co. KG (dievini) has  committed
financial funds of euro 6 million on the basis of a  loan  agreement.  Based  on
dievini´s commitment these funds shall be invested within this capital  increase
in receipt of new shares worth up to  euro  6  million.  Accordingly,  the  loan
amount will be reduced by the amount which dievini will invest as part  of  this
capital increase.

An organized trade in subscription rights will not occur. The  approval  of  the
new shares  for  trading  in  the  regulated  market  (Prime  Standard)  at  the
Frankfurt Stock Exchange is not expected before 17 August 2011. Further  details
of the capital increase will be provided in the subscription offer  expected  to
be published in the electronic Federal Gazette  (elektronischer  Bundesanzeiger)
on 25 August 2011. The  capital  increase  is  conducted  by  Landesbank  Baden-

The  proceeds  are  to  be  used  for  financing  SYGNIS´  existing  operations,
according to the  present  plans,  at  least  until  the  end  of  2012  and  in
particular for the completion of the current efficacy trial for  AX200  for  the
treatment of acute stroke (AXIS 2) and the potential commercialization  of  this

For further information please contact:

|Dr. Franz-Werner Haas                   |
|Senior VP  Operations                   |
|Tel: +49 (0) 6221-454 812               |
|Email:   |

This publication is intended for information only and constitutes neither an
offer to sell nor an invitation to buy securities. The shares in SYGNIS Pharma
AG (the 'Shares') may not be offered or sold in the United States or to or for
the account or benefit of 'U.S. persons' (as such term is defined in Regulation
S under the U.S. Securities Act of 1933, as amended (the 'Securities Act')). No

offer or sale of transferable securities is being made to the public. The
shares are offered solely on the basis of subscription rights.
This document is only being distributed to and is only directed at (i) persons
who are outside the United Kingdom or (ii) to investment professionals falling
within Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the 'Order') or (iii) high net worth entities, and other
persons to whom it may lawfully be communicated, falling within Article
49(2)(a) to (d) of the Order (all such persons together being referred to as
'relevant persons'). The Shares are only available to, and any invitation,
offer or agreement to subscribe, purchase or otherwise acquire such securities
will be engaged in only with, relevant persons. Any person who is not a
relevant person should not act or rely on this document or any of its contents.

Some statements included in this press release, relating neither to proven
financial results nor other historical data, should be viewed as forward-
looking, i.e. not definite. Such statements are mainly predictions of future
results, trends, plans or goals. These statements should not be considered to
be total guarantees since given their very nature they are subject to known and
unknown risks and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS Pharma AG
may deviate greatly from the established conclusions or implied predictions
contained in such statements. SYGNIS does not undertake to publicly update or
revise these statements in the light of new information or future results or
for any other reason.

Further inquiry note:
Michael Wolf
Telefon: +49 (6221) 454 - 6

end of announcement                               euro adhoc 

issuer:      SYGNIS Pharma AG
             Im Neuenheimer Feld 515
             D-69120 Heidelberg
phone:       +49 (0)6221 454-6
FAX:         +49 (0)6221 454-777
sector:      Biotechnology
ISIN:        DE000A1E9B74
indexes:     CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
             Hamburg, Stuttgart, Düsseldorf, Hannover, München 
language:   English

Weitere Meldungen: SYGNIS AG

Das könnte Sie auch interessieren: